Efficacy of Pemafibrate Against Nonalcoholic Fatty Liver Disease: A Prospective Cohort Study
1. Abstract 1.1. Background: Nonalcoholic fatty liver disease (NAFLD), one of the most common causes of chronic liver diseases, is characterized by chronic liver inflammation and fibrosis, which consequently promote cirrhosis and liver cancer. Pemafibrate, a selective PPARα modulator is a new lipid-lowering drug that provides better hypertriglyceridemia control compared to greater other fibrates without …